GlaxoSmithKline makes $300M investment in 23andMe, forms 50-50 R&D pact
Make no mistake about what is happening here. GSK is buying access to all of the genetic data that 23andMe has. This is why I am wary to use any 23andMe type of service."The partners plan to use 23andMe’s data to jointly discover drug targets."They will claim all kinds of protections of course, but it is only a matter of time until genetic data starts being resold.